How Zilganersen’s Positive Pivotal Data and FDA Priority Review Could Impact Ionis Pharmaceuticals (IONS) Investors

Simply Wall St.02:05

Ionis Pharmaceuticals recently reported additional positive results from its pivotal Phase 1-3 trial of zilganersen in Alexander disease, showing statistically significant stabilization of gait speed ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629024160?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-23 02:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629024160","market":"us","top_or_hot":-1,"title":"How Zilganersen’s Positive Pivotal Data and FDA Priority Review Could Impact Ionis Pharmaceuticals (IONS) Investors","media":"Simply Wall St.","content":"<div>\n<p>Ionis Pharmaceuticals recently reported additional positive results from its pivotal Phase 1-3 trial of zilganersen in Alexander disease, showing statistically significant stabilization of gait speed ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/how-zilganersens-positive-pivotal-data-and-fda-priority-revi\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Zilganersen’s Positive Pivotal Data and FDA Priority Review Could Impact Ionis Pharmaceuticals (IONS) Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Zilganersen’s Positive Pivotal Data and FDA Priority Review Could Impact Ionis Pharmaceuticals (IONS) Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-23 02:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/how-zilganersens-positive-pivotal-data-and-fda-priority-revi><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ionis Pharmaceuticals recently reported additional positive results from its pivotal Phase 1-3 trial of zilganersen in Alexander disease, showing statistically significant stabilization of gait speed ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/how-zilganersens-positive-pivotal-data-and-fda-priority-revi\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/how-zilganersens-positive-pivotal-data-and-fda-priority-revi","article_id":"2629024160","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/how-zilganersens-positive-pivotal-data-and-fda-priority-revi","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2629024160","pubTimestamp":1776881149,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ionis Pharmaceuticals recently reported additional positive results from its pivotal Phase 1-3 trial of zilganersen in Alexander disease, showing statistically significant stabilization of gait speed and broad symptom benefits over 60 weeks, with the drug currently under FDA Priority Review and a PDUFA decision date set for September 22, 2026.\nBeyond motor endpoints, exploratory data showing reduced glial fibrillary acidic protein levels and consistently better patient- and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IONS":"Ionis Pharmaceuticals, Inc","ISBC":"投资者银行","BK4211":"区域性银行","LABU":"三倍做多标普生物-Direxion","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Zilganersen的积极关键数据和FDA优先审查将如何影响Ionis Pharmaceuticals(IONS)投资者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"ISBC":1.5,"IONS":1.5},"content_text":"Ionis Pharmaceuticals recently reported additional positive results from its pivotal Phase 1-3 trial of zilganersen in Alexander disease, showing statistically significant stabilization of gait speed and broad symptom benefits over 60 weeks, with the drug currently under FDA Priority Review and a PDUFA decision date set for September 22, 2026. Beyond motor endpoints, exploratory data showing reduced glial fibrillary acidic protein levels and consistently better patient- and clinician-reported outcomes highlight zilganersen’s potential as a first disease-modifying therapy for this ultra-rare, often fatal neurological disorder. Next, we’ll examine how zilganersen’s positive pivotal outcomes and FDA Priority Review may influence Ionis’s investment narrative and perceived pipeline strength. The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AdvertisementIonis Pharmaceuticals Investment Narrative RecapTo own Ionis today, you need to believe its RNA platform and growing commercial portfolio can convert late-stage assets into durable, profitable revenue streams. The zilganersen update strengthens Ionis’s case in ultra-rare neurology and adds weight to the upcoming FDA decision in Alexander disease, but the near term still hinges more on execution and pricing outcomes for Olezarsen in severe hypertriglyceridemia and the broader risk that key regulatory timelines slip. The most relevant recent development alongside zilganersen is the FDA’s Priority Review of Olezarsen’s sNDA in severe hypertriglyceridemia, with a PDUFA date of June 30, 2026. Together, these back-to-back priority reviews highlight how concentrated Ionis’s near term catalysts are in a handful of late-stage programs, which can magnify both the upside if approvals arrive as planned and the downside if pricing or label discussions constrain commercial potential. Yet behind these promising catalysts, investors should also be aware that pricing pressure on Olezarsen across FCS and sHTG could... Read the full narrative on Ionis Pharmaceuticals (it's free!)Ionis Pharmaceuticals’ narrative projects $1.9 billion revenue and $82.2 million earnings by 2029. This requires 27.3% yearly revenue growth and a roughly $463.6 million earnings improvement from -$381.4 million today.Uncover how Ionis Pharmaceuticals' forecasts yield a $96.73 fair value, a 29% upside to its current price.Exploring Other PerspectivesIONS 1-Year Stock Price Chart While consensus already saw strong growth ahead, some of the most optimistic analysts were modeling revenue near US$2.9 billion and earnings around US$640.8 million by 2029, so this new zilganersen data could either reinforce or challenge those expectations depending on how you view the added regulatory risk in ultra rare diseases and the possibility that key approvals arrive on a different timeline than initially assumed.Explore 3 other fair value estimates on Ionis Pharmaceuticals - why the stock might be worth over 3x more than the current price!The Verdict Is YoursDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Ionis Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free Ionis Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ionis Pharmaceuticals' overall financial health at a glance.Interested In Other Possibilities?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.Uncover the next big thing with 28 elite penny stocks that balance risk and reward.Find 58 companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629024160","isCrawlerRequest":true}